EGFR G719S
|
NSCLC
|
EGFR G719S
|
NSCLC
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR G719S
|
NSCLC
|
EGFR G719S
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719S
|
NSCLC
|
EGFR G719S
|
NSCLC
|
osimertinib Sensitive: C3 – Early Trials
|
osimertinib Sensitive: C3 – Early Trials
|
EGFR G719S
|
LUAD
|
EGFR G719S
|
LUAD
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|
EGFR G719S
|
Colon Cancer
|
EGFR G719S
|
Colon Cancer
|
ABP 494 (cetuximab biosimilar) Sensitive: D – Preclinical
|
ABP 494 (cetuximab biosimilar) Sensitive: D – Preclinical
|
EGFR G719S
|
Colon Cancer
|
EGFR G719S
|
Colon Cancer
|
cetuximab Sensitive: D – Preclinical
|
cetuximab Sensitive: D – Preclinical
|
EGFR G719S
|
Colon Cancer
|
EGFR G719S
|
Colon Cancer
|
panitumumab Sensitive: D – Preclinical
|
panitumumab Sensitive: D – Preclinical
|